Clearmind Medicine reports positive preclinical data for cocaine addiction treatment

Clearmind Medicine (CSE:CMND) recently announced additional positive preclinical data related to its psychedelic molecule 5-methoxy-2-aminoindane (MEAI) for treating cocaine addiction.

Professor Gal Yadid and a group of researchers from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel) performed the study based on the self-administration paradigm, which is an operant-conditioning-based model for investigating drug addiction.

In the study, rats were trained to self-administer cocaine and underwent an extinction phase in which researchers removed cocaine availability. Researchers then provided MEAI to the test group. Afterward, the researchers offered a single administration of cocaine to the rats who

were later returned to their self-administration habitat.

Animals that received MEAI had a substantially lower likelihood of attempting to self-administer cocaine.

Read more

  • 0